SVB raises Biogene's PT on expected success of leukemia drug
12/12/2022 17:31
** SVB raises PT for drug developer BeiGene Ltd BGNE.O to $236
from $210; maintains "outperform" rating
** Says survey of physicians treating chronic
lymphocytic leukemia reveals that co's Brukinsa drug can achieve
significant market share for the disorder, following approval
** Brukinsa has already received FDA approval to treat other
disorders
** Eighteen out of 19 brokerages rate the stock "buy" or
higher and 1 "hold"; median PT is $255.56 - Refinitiv IBES
** The stock is down ~26% YTD, including session moves
(Reporting by Anirban Chakroborti in Bengaluru)
((Anirban.Chakroborti@thomsonreuters.com;))